BioNTech faces its biggest post pandemic crisis
Six years after BioNTech, a then little-known German biotech firm, developed the first approved mRNA COVID-19 vaccine and helped change the course of the pandemic, the company is now navigating its most difficult period since that breakthrough. The Mainz-based firm announced a sweeping restructuring plan that includes closing production sites, cutting thousands of jobs, and a strategic pivot toward cancer research, according to reports from Deutsche Welle.
The company, which partnered with Pfizer to roll out its Comirnaty vaccine in record time, is now winding down its COVID vaccine production entirely, leaving future manufacturing to its US partner. "In the course of this year we will produce the last doses here in Germany," a company spokeswoman told Reuters, as cited by Deutsche Welle.
Financial losses and restructuring
BioNTech reported a net quarterly loss of €531.9 million, according to Deutsche Welle. The company's revenues for the first quarter of 2026 dropped to €118.1 million, a 35% decline compared to the same period last year. The firm said it "anticipates lower COVID-19 vaccine revenues compared to 2025, driven by declines in both the European and United States markets."
Analysts attribute the sharp downturn to the predictable end of the COVID-19 windfall, which had generated tens of billions of euros in revenue since late 2020. They also point to the high-risk nature of biotech research and development, compounded by Germany's economic challenges, including high labor and energy costs and bureaucratic hurdles. As one analyst put it, the company's overreliance on a single blockbuster product exposed its vulnerability.
Production site closures and job cuts
As part of the restructuring, BioNTech is closing production centers in Idar-Oberstein and Marburg in Germany, Singapore, and a facility in Tübingen that was acquired from CureVac. The Tübingen site, which BioNTech fully took over in late 2025 after a lengthy acquisition, will be closed and possibly sold. The company said the closures should be completed by the end of 2027 and that it would explore selling the affected facilities.
BioNTech had previously announced it would cut between 950 and 1,350 full-time jobs over two years. With the expanded restructuring, the company now says up to 1,860 jobs could be affected in total. The exact number of jobs already cut has not been disclosed.
Funders' departure and shift to cancer research
The company is also bracing for the departure of its founders, Ugur Sahin and Özlem Türeci, who are leaving to start a new firm. Their exit marks the end of an era for the company that rose to global prominence under their leadership.
BioNTech is now shifting its focus to late-stage mRNA treatments for cancer and other illnesses, hoping to replicate its COVID success in oncology. The company is investing heavily in this research, despite current losses, in anticipation of future payouts from clinical trials.
Perspectives
From a business perspective, the restructuring is seen as a necessary adaptation to a post-pandemic reality where COVID vaccine demand has fallen sharply. For employees and local communities, the closure of production sites and job losses represent a significant blow. Meanwhile, the founders' departure raises questions about BioNTech's long-term vision and its ability to innovate outside the COVID spotlight.
As BioNTech navigates this transition, the company's fate will depend on the success of its cancer treatments and its ability to move beyond its pandemic-era identity.